Both authors contributed equally to the work presented here.
1755-3768/asset/olbannercenter.gif?v=1&s=baf172706d8b0315485b0acf45bb6cfebe7a6ecc)
You have full text access to this OnlineOpen article
The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization
Article first published online: 22 JUN 2009
DOI: 10.1111/j.1755-3768.2009.01571.x
© 2009 The Authors. Journal compilation © 2009 Acta Ophthalmol
Additional Information
How to Cite
Habot-Wilner, Z., Barequet, I. S., Ivanir, Y., Moisseiev, J. and Rosner, M. (2010), The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmologica, 88: 862–867. doi: 10.1111/j.1755-3768.2009.01571.x
Publication History
- Issue published online: 22 JUN 2009
- Article first published online: 22 JUN 2009
- Received on July 31st, 2008. Accepted on January 31st, 2009.
- Abstract
- Article
- References
- Cited By
Keywords:
- anti-angiogenic drugs;
- bevacizumab;
- chemical burns;
- corneal neovascularization
Acta Ophthalmol. 2010: 88: 862–867
Abstract.
Purpose: This study aimed to evaluate the effects of different concentrations of topically administered bevacizumab (Avastin) on experimental corneal neovascularization (NV) in rats.
Methods: Corneal NV was induced by chemical cauterization with silver nitrate sticks applied to the centre of the corneas of 37 Wistar rats. The rats were then randomized to four topical treatment groups: group 1 (n = 10) received 4 mg/ml bevacizumab; group 2 (n = 9) received 2 mg/ml bevacizumab; group 3 (n = 10) received 1 mg/ml bevacizumab, and group 4 (n = 8) represented a control group and received saline. All drops were initiated immediately after cauterization and applied twice per day for 7 days. Corneal NV was assessed 8 days after cauterization in a masked fashion, both qualitatively by clinical evaluation and quantitatively by blood vessel count in photographs of histological sections.
Results: On clinical evaluation, groups 1 and 2 showed significantly less NV compared with the saline-treated control group (p = 0.006 and p = 0.024, respectively). Histopathological evaluation showed that only group 1 differed significantly from controls (5% significance level) and normal corneal epithelium was seen in all groups.
Conclusions: Topically administered bevacizumab at a concentration of 4 mg/ml significantly reduces corneal NV according to both clinical and histopathological evaluations; lower concentrations were less effective on both parameters. No corneal epitheliopathy was found using these concentrations.